F
Frances M. Boyle
Researcher at Mater Health Services
Publications - 364
Citations - 11873
Frances M. Boyle is an academic researcher from Mater Health Services. The author has contributed to research in topics: Breast cancer & Population. The author has an hindex of 55, co-authored 336 publications receiving 9788 citations. Previous affiliations of Frances M. Boyle include Royal North Shore Hospital & University of Newcastle.
Papers
More filters
Journal ArticleDOI
Stillbirths: recall to action in high-income countries
Vicki Flenady,Aleena M. Wojcieszek,Philippa Middleton,David Ellwood,Jan Jaap H. M. Erwich,Michael Coory,T. Yee Khong,Robert M. Silver,Gordon C. S. Smith,Frances M. Boyle,Joy E Lawn,Hannah Blencowe,Susannah Hopkins Leisher,Mechthild M. Gross,Mechthild M. Gross,Dell Horey,Dell Horey,Lynn Farrales,Frank H. Bloomfield,Lesley M. E. McCowan,Stephanie Brown,K.S. Joseph,Jennifer Zeitlin,Hanna E. Reinebrant,Claudia Ravaldi,Alfredo Vannacci,Jillian Cassidy,Paul Cassidy,Cindy Farquhar,Euan M. Wallace,Dimitrios Siassakos,Dimitrios Siassakos,Alexander E. P. Heazell,Alexander E. P. Heazell,Claire Storey,Lynn Sadler,Scott Petersen,Scott Petersen,J. Frederik Frøen,Robert L. Goldenberg +39 more
TL;DR: In high-income countries, a woman living under adverse socioeconomic circumstances has twice the risk of having a stillborn child when compared to her more advantaged counterparts and programs at community and country level need to improve health in disadvantaged families.
Journal ArticleDOI
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Halle C. F. Moore,Joseph M. Unger,Kelly-Anne Phillips,Frances M. Boyle,Frances M. Boyle,Erika Hitre,David L. Porter,Prudence A. Francis,Lori J. Goldstein,Henry L. Gomez,Carlos S. Vallejos,Ann H. Partridge,Shaker R. Dakhil,Agustin A. Garcia,Julie R. Gralow,Janine M. Lombard,John F. Forbes,Silvana Martino,William E. Barlow,Carol J. Fabian,Lori M. Minasian,Frank L. Meyskens,Richard D. Gelber,Gabriel N. Hortobagyi,Kathy S. Albain +24 more
TL;DR: Although missing data weaken interpretation of the findings, administration of goserelin with chemotherapy appeared to protect against ovarian failure, reducing the risk of early menopause and improving prospects for fertility.
Journal ArticleDOI
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja,Andrew P. Holmes,Martine Piccart-Gebhart,Eileen Holmes,Serena Di Cosimo,Ramona F. Swaby,Michael Untch,Christian Jackisch,István Láng,Ian E. Smith,Frances M. Boyle,Binghe Xu,Carlos H. Barrios,Edith A. Perez,Hatem A. Azim,Sung Bae Kim,Sherko Kuemmel,Chiun-Sheng Huang,Peter Vuylsteke,Ruey Kuen Hsieh,Vera Gorbunova,Alexandru Eniu,Lydia Dreosti,Natalia Tavartkiladze,Richard D. Gelber,Holger Eidtmann,José Baselga +26 more
TL;DR: The NeoALTTO trial showed that 3-year event-free survival was significantly improved for women who achieved pathological complete response compared with those who did not, and the association between pathological complete responded and overall survival was assessed.
Journal ArticleDOI
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Martine Piccart-Gebhart,Eileen Holmes,Jośe Baselga,Evandro de Azambuja,Amylou C. Dueck,Giuseppe Viale,Jo Anne Zujewski,Aron Goldhirsch,A Armour,Kathleen I. Pritchard,Ann E. McCullough,Stella Dolci,Eleanor McFadden,Andrew P. Holmes,Liu Tong-hua,Holger Eidtmann,Phuong Dinh,Serena Di Cosimo,Nadia Harbeck,Sergei Tjulandin,Young-Hyuck Im,Chiun-Sheng Huang,Véronique Diéras,David W. Hillman,Antonio C. Wolff,Christian Jackisch,István Láng,Michael Untch,Ian E. Smith,Frances M. Boyle,Binghe Xu,Henry L. Gomez,Thomas M. Suter,Richard D. Gelber,Edith A. Perez +34 more
TL;DR: Adjuvant treatment that includes L did not significantly improve DFS compared with T alone and added toxicity, and one year of adjuvant T remains standard of care.
Journal ArticleDOI
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Sherene Loi,Anita Giobbie-Hurder,Andrea Gombos,Thomas Bachelot,Rina Hui,Giuseppe Curigliano,Giuseppe Curigliano,Mario Campone,Laura Biganzoli,Hervé Bonnefoi,Guy Jerusalem,Rupert Bartsch,Manuela Rabaglio-Poretti,Roswitha Kammler,Rudolf Maibach,Mark J. Smyth,Angelo Di Leo,Marco Colleoni,Giuseppe Viale,Giuseppe Viale,Meredith M. Regan,Fabrice Andre,Debora Fumagalli,Richard D. Gelber,Theodora Goulioti,Anita Hiltbrunner,Rita Hui,Heidi Roschitzki,Barbara Ruepp,Frances M. Boyle,Rolf A. Stahel,Stefan Aebi,Alan S. Coates,Aron Goldhirsch,Per Karlsson,Ingrid Kössler,Stamatina Fournarakou,Adriana Gasca,Rita Pfister,Sabrina Ribeli-Hofmann,Magdelena Weber,Daniela Celotto,Carmen Comune,Michela Frapolli,Magdalena Sánchez-Hohl,Hui Huang,Caitlin Mahoney,Karen N. Price,Karolyn Scott,Holly Shaw,Susan Fischer,Monica Greco,Colleen King,Stefania Andrighetto,Martine Piccart-Gebhart,Heather Findlay,Michelle Jenkins,Vassiliki Karantza,Jaime A. Mejia,Patrick Schneier +59 more
TL;DR: This single-arm, multicentre, phase 1b-2 trial assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added to trastuzumab in trastzumab-resistant, advanced HER2-positive breast cancer.